Event-Driven Stocks

INCYTE CORP

INCYNasdaq

Industrials · Services-Commercial Physical & Biological Research · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 7 gooddetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$5.14B$4.24B$3.70B$3.39B$2.99B$2.67B
Operating income$1.51B$61.4M$620.5M$579.4M$585.8M−$263.7M
Net income$1.29B$32.6M$597.6M$340.7M$948.6M−$295.7M
Total assets$6.96B$5.44B$6.78B$5.84B$4.93B$3.56B
Total liabilities$1.79B$2.00B$1.59B$1.47B$1.16B$949.6M
Equity$5.17B$3.45B$5.19B$4.37B$3.77B$2.61B
EPS (diluted)$6.41$0.15$2.65$1.52$4.27$-1.36
Shares out.193.5M224.5M223.0M221.3M219.8M216.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
29.5%
Net margin
25.0%
Return on equity
24.9%
Return on assets
18.5%
Return on capital (ROCE)
27.8%
Liabilities / assets
25.7%
Debt / equity
0.35×
Book value / share
$26.70
Revenue growth (YoY)
21.2%
Net income growth (YoY)
3845.0%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
7.90safe
Accruals / assets
−1.8%clean
Piotroski F-Score
8/9strong

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
93
/ 100
Profitability 100Growth 100Catalyst 67Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 7 good
  • Operating margin is positive
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Positive operating cash flow
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202611.0M8.7-2.8%
Apr 30, 202611.4M7.0-5.2%
Apr 15, 202612.0M9.8+4.6%
Mar 31, 202611.4M6.6+3.6%
Mar 13, 202611.0M7.0+0.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.